Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1479

Sort by

Sort Order Select

Journal Articles

Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens

Blood Adv bloodadvances.2024014181.

https://doi.org/10.1182/bloodadvances.2024014181

Published: 2025

Journal Articles

Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection

Ilske Oschlies, Julia Richter, Amelie Alfert, Fernando Chahud, Stephanie Mueller, Ingrid Simonitsch-Klupp, Hannah von Mersi, Andishe Attarbaschi, Karoline Koch, Christoph Schaefers, Monika Brüggemann, Cecilia Bozzetti, Wilhelm Woessmann, Birgit Burkhardt, Wolfram Klapper

Blood Adv bloodadvances.2025016596.

https://doi.org/10.1182/bloodadvances.2025016596

Published: 2025

Includes: Supplemental data

Journal Articles

Blinatumomab Use in Pediatric B-ALL: Where are we now?

Anurekha G Hall, Rachel E Rau

Blood Adv bloodadvances.2024014043.

https://doi.org/10.1182/bloodadvances.2024014043

Published: 2025

Journal Articles

Thyroid hormones contribute to JAK/STAT pathway abnormal activation promoting T-cell lymphoma dissemination

María Mercedes Debernardi, Alejandro Correa, Lucero Alvarado, María V. Revuelta, Helena Andrea Sterle, Gonzalo Gonzalez, Ingrid Larissa Melo Souza, Jorgelina Nelly Real, Dra, María Teresa Garcia de Dávila, Johanna Abigail Diaz Albuja, Cinthia Rosemblit, Leandro Cerchietti, Graciela A Cremaschi, Florencia Cayrol

Blood Adv bloodadvances.2024015332.

https://doi.org/10.1182/bloodadvances.2024015332

Published: 2025

Includes: Supplemental data

Journal Articles

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Alexey V Danilov, Swetha Thiruvengadam, Kim Linton, Karen Cumings, Viktor V Chirikov, Alex Mutebi, Savreet Bains Chawla, Anindit Chhibber, Fernando Rivas Navarro, Felipe Marques Gonçalves, Anthony Wang, Zhijie Ding, Abualbishr Alshreef, Elena Favaro, Daniela Hoehn, Anna Sureda

Blood Adv bloodadvances.2024015274.

https://doi.org/10.1182/bloodadvances.2024015274

Published: 2025

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Blood Adv (2025) 9 (11): 2808–2817.

https://doi.org/10.1182/bloodadvances.2025016006

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Blood Adv (2025) 9 (11): 2763–2772.

https://doi.org/10.1182/bloodadvances.2024014846

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review

Aisling Barrett, Callum Harris, Toby A. Eyre

Blood Adv (2025) 9 (11): 2773–2780.

https://doi.org/10.1182/bloodadvances.2024015594

Published: 2025

Journal Articles

Estrogen receptor β stimulation as a possible novel therapeutic target for cutaneous T-cell lymphoma

Blood Adv (2025) 9 (11): 2651–2662.

https://doi.org/10.1182/bloodadvances.2024015132

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

Blood Adv (2025) 9 (11): 2663–2676.

https://doi.org/10.1182/bloodadvances.2024013656

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders

Blood Adv bloodadvances.2024015406.

https://doi.org/10.1182/bloodadvances.2024015406

Published: 2025

Includes: Supplemental data

Journal Articles

Circulating Tumor DNA Determinants of Response and Outcome in Relapsed/Refractory Mantle Cell Lymphoma

Leo Meriranta, Rasmus Rask Kragh Jørgensen, Annika Pasanen, Arne Kolstad, Martin Hutchings, Carsten Utoft Niemann, Tarec Christoffer El Galaly, Jon Riise, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius, Sirpa Leppä, Mats Jerkeman

Blood Adv bloodadvances.2025015791.

https://doi.org/10.1182/bloodadvances.2025015791

Published: 2025

Includes: Supplemental data

Journal Articles

Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism

Axel Künstner, Vera von Kopylow, Philipp Lohneis, Matthias Kümmel, Hanno M. Witte, Dr, Lorenz Bastian, Veronica Bernard, Dr, Stephanie Stölting, Kathrin Kusch, Nikolas von Bubnoff, Konrad Steinestel, Annette Arndt, Hartmut Merz, Prof, Hauke Busch, Alfred C. Feller, Niklas Gebauer

Blood Adv bloodadvances.2025016002.

https://doi.org/10.1182/bloodadvances.2025016002

Published: 2025

Includes: Supplemental data

Journal Articles

Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study

Xavier Phina-Ziebin, Emmanuel Bachy, François-Xavier Gros, Roberta Di Blasi, Charles Herbaux, Jacques Olivier Bay, Sylvain Carras, Pierre Bories, Olivier Casasnovas, Fabrice Jardin, Franck Morschhauser, Blandine Guffroy, Mohamad Mohty, Elodie Gat, Julien Calvani, Marie-Cécile Parrens, Elsa Poullot, Alexandra Traverse-Glehen, Louise Roulin

Blood Adv (2025) 9 (10): 2500–2510.

https://doi.org/10.1182/bloodadvances.2024014732

Published: 2025

Includes: Supplemental data

Journal Articles

Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model

Wael Gamal, Nienke B. Goedhart, Helga Simon-Molas, Melanie Mediavilla-Varela, Angimar Uriepero-Palma, Fleur S. Peters, Kamira Maharaj, Julio C. Chavez, John Powers, Alyssa Obermayer, Timothy I. Shaw, José R. Conejo-Garcia, Paulo C. Rodriguez, Eva Sahakian, Javier Pinilla-Ibarz, Arnon P. Kater

Blood Adv (2025) 9 (10): 2511–2529.

https://doi.org/10.1182/bloodadvances.2024014822

Published: 2025

Includes: Supplemental data

Journal Articles

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study

Jason Westin, Tycel J. Phillips, Amitkumar Mehta, Marc S. Hoffmann, Eva Gonzalez-Barca, Catherine Thieblemont, Mariana Bastos-Oreiro, Richard Greil, Sebastian Giebel, Michael C. Wei, Jue Wang, Reinhard Bucher, Jason Sit, Elicia Penuel, Enkhtsetseg Purev, Donald L. Yee, Juan Miguel Bergua-Burgues

Blood Adv (2025) 9 (10): 2461–2472.

https://doi.org/10.1182/bloodadvances.2024014907

Published: 2025

Includes: Supplemental data

Journal Articles

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Bei Hu, Patrick M. Reagan, Laurie H. Sehn, Jeff P. Sharman, Mark Hertzberg, Huilai Zhang, Austin Kim, Charles Herbaux, Lysiane Molina, Dai Maruyama, Frank Stenner, Saibah Chohan, Rucha Kothari, Connie Lee Batlevi, Jamie Hirata, Deniz Sahin, Calvin Lee, Matthew Sugidono, Hervé Tilly

Blood Adv (2025) 9 (10): 2489–2499.

https://doi.org/10.1182/bloodadvances.2024014707

Published: 2025

Includes: Supplemental data

Journal Articles

What to do with the weight while preparing for CAR-T?

Samuel J. Yates, Ishan Roy

Blood Adv (2025) 9 (10): 2419–2421.

https://doi.org/10.1182/bloodadvances.2024015429

Published: 2025

Journal Articles

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells

Sara E. F. Kost, Ali Saleh, Jennifer Brown, Shek H. Yuan, Bozena Kuzio, Lin Yang, Versha Banerji, Spencer B. Gibson, James B. Johnston, Sachin Katyal

Blood Adv (2025) 9 (10): 2422–2427.

https://doi.org/10.1182/bloodadvances.2024014407

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia

Valentin Goede, Kirsten Fischer, Sandra Robrecht, Adam Giza, Martin J. S. Dyer, Michael J. Eckart, Lothar Mϋller, Lukáš Smolej, Nadine Kutsch, Anna-Maria Fink, Stephan Stilgenbauer, Michael Hallek

Blood Adv (2025) 9 (10): 2431–2435.

https://doi.org/10.1182/bloodadvances.2024014875

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens

Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection

Blinatumomab Use in Pediatric B-ALL: Where are we now?

Thyroid hormones contribute to JAK/STAT pathway abnormal activation promoting T-cell lymphoma dissemination

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review

Estrogen receptor β stimulation as a possible novel therapeutic target for cutaneous T-cell lymphoma

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders

Circulating Tumor DNA Determinants of Response and Outcome in Relapsed/Refractory Mantle Cell Lymphoma

Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism

Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study

Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

What to do with the weight while preparing for CAR-T?

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only